The MINT Study: addressing unmet need in high-risk neuroblastoma

This recorded session from Solving Kids’ Cancer UK’s 2026 Neuroblastoma Parent Symposium provides an accessible overview of the MINT study, which is exploring whether combining targeted radiotherapy with a PARP inhibitor can make treatment more effective, particularly for children whose tumours have specific genetic features. It also looks at how the study aims to address gaps in treatment for certain high‑risk neuroblastoma subgroups, such as ATRX‑driven disease.